The Colorado Prescription Drug Affordability Board blinked. On Friday, they had a chance to deem Vertex’s CF drug, Trikafta, as the first-ever “unaffordable” medicine, thereby opening the medicine to price

So, the plan this morning was to give an exhaustive breakdown of all of the comments and commentary about the Biden administration’s move to set a path for using march-in

I only really want two things this holiday season. The first is good, old-fashioned eggnog. The other is the knowledge that Cost Curve is making it to people who would

I might be squinting at the issue too hard, but my takeaway from this well-done USA Today piece about the legal battle over copay accumulators is that, maybe, the Biden

Congrats to patient advocate/CEO John Crowley, who will be taking over as the CEO of the Biotechnology Innovation Organization. No one knows the stakes of drug development better than John,

There may be no drug-pricing myth more pernicious than the idea that the NIH does all the drug research, and companies just sweep in at the eleventh hour, ram medicines

It’s World AIDS Day today. This used to be a much high-profile event, with consistent media coverage. That’s changed, slowly, over the two decades or so, which -- I fear

I’m finally through uploading the transcripts from almost all** of the CMS patient-focused listening sessions around the 10 drugs slated for price controls under the Inflation Reduction Act. You can

There’s a lot to go through this morning. Let’s get at it. I’m thinking about rare diseases this morning for a couple of reasons.  First, there is this JAMA Internal

I’ve been on the record for a while now arguing that the conversation around obesity medicines ought not be a debate about whether the medicines are “worth it” -- it